What’s the current market cap for LeMaitre Vascular stock?

LeMaitre Vascular (LMAT) has a market cap of $2.2B as of May 25, 2026.

What is the P/E ratio for LeMaitre Vascular stock?

The price to earnings (P/E) ratio for LeMaitre Vascular (LMAT) stock is 35.94 as of May 25, 2026.

Does LeMaitre Vascular stock pay dividends?

Yes, the LeMaitre Vascular (LMAT) stock pays dividends to shareholders. As of May 25, 2026, the dividend rate is $0.85 and the yield is 1.02%. LeMaitre Vascular has a payout ratio of 30.93% on a trailing twelve-month basis.

When is the next LeMaitre Vascular dividend payment date?

The next LeMaitre Vascular (LMAT) dividend payment is scheduled for June 04, 2026.

What is the beta indicator for LeMaitre Vascular?

LeMaitre Vascular (LMAT) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy LeMaitre Vascular stock | $LMAT Share Price

13:30

15:10

16:45

18:25

20:00

About LeMaitre Vascular

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

Ticker

$LMAT

Sector

Health

Primary listing

NASDAQ

Employees

651

Headquarters

Burlington, United States

Website

www.lemaitre.com

LMAT Metrics

BasicAdvanced

$2.2bn

35.94

$2.72

0.60

$0.85

1.02%

What the Analysts think about LMAT

Analyst ratings (Buy, Hold, Sell) for LeMaitre Vascular stock.

Bulls say / Bears say

LeMaitre reported Q1 2026 sales of $66.6 million, an increase of 11% year-over-year (10% organic) from Q1 2025, and diluted EPS rose 42% to $0.68, showing strong demand for grafts, valvulotomes, and carotid shunts worldwide (Nasdaq).

Gross margin increased by 350 basis points to 72.7% in Q1 2026, while operating margin improved to 27%. This was due to higher average selling prices and greater manufacturing efficiency, highlighting LeMaitre’s pricing power and operational scale (Nasdaq).

Growth is being driven by regulatory milestones and new products: Artegraft received approval in 52 markets and delivered $2.1 million in international sales in Q1, while XenoSure vascular applications have been submitted in China, expanding the total addressable market for core businesses (LeMaitre Investor Presentation).

Stauder’s recent note points out LeMaitre has expanded its operating margin by about 700 basis points since fiscal 2023, raising concerns over whether further margin improvements are sustainable for this small-cap MedTech company (Investing.com).

LeMaitre is trading at a premium valuation, with a forward P/E of 35.7× and trailing P/E of 40.2×, well above the medical equipment sector average of roughly 33×, which could restrict further upside from valuation multiple expansion (StockAnalysis).

Management has shown caution in providing detailed guidance for particular product lines, indicating uncertainty in the market that may cause volatility in sales for key products (GuruFocus).

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

LMAT Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

LMAT Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LMAT

Capital at risk

Market closed

Upcoming events

Bulls say / Bears say

Management has shown caution in providing detailed guidance for particular product lines, indicating uncertainty in the market that may cause volatility in sales for key products (GuruFocus).

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

About LeMaitre Vascular

Ticker

Employees

LMAT Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about LMAT

Analyst Ratings

Bulls say / Bears say

LMAT Financial Performance

Income Statement

LMAT Earnings Performance

Earnings per share (EPS)

Buy $LMAT

Upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

LeMaitre Vascular/$LMAT

About LeMaitre Vascular

Ticker

Employees

LMAT Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about LMAT

Analyst Ratings

Bulls say / Bears say

LMAT Financial Performance

Income Statement

LMAT Earnings Performance

Earnings per share (EPS)

Buy $LMAT

Upcoming events

What’s the current market cap for LeMaitre Vascular stock?

What is the P/E ratio for LeMaitre Vascular stock?

Does LeMaitre Vascular stock pay dividends?

When is the next LeMaitre Vascular dividend payment date?

What is the beta indicator for LeMaitre Vascular?

Bulls say / Bears say